Byondis   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Nijmegen Netherlands (1991)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2011
NCT01489254
First Marketed Drug
2001
fluvoxamine (luvox)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Byondis B.V. | Byondis B.V., The Netherlands | Synthon Biopharmaceuticals | Synthon Biopharmaceuticals BV | Synthon Biopharmaceuticals BV, The Netherlands | Synthon BV | SYNTHON PHARMS